fashion -WSS

fashion

author：leisure time 2025-08-23 05:01:56 - browse：87763

Eli Lilly headquarters — Kristoffer Tripplaar/AP

Eventually, the luckiest companies get to deal with a very particular problem: what to do when their stock could be getting ahead of itself.

It’s a problem Eli Lilly got a little taste of Tuesday when it announced its full-year earnings. The drugmaker’s stock has more than doubled over the past 12 months due to the ever-increasing hopes for its GLP-1-based diabetes and weight loss drug, sold under the brand names Mounjaro and Zepbound. It was a big deal when Lilly became the first drug company ever to have a market value of $500 billion; it’s now sitting at a stunning $670 billion.

At first, the earnings report suggested the company had blasted through expectations again, announcing fourth-quarter 2023 sales of $9.35 billion, almost half a billion dollars above analysts’ expectations, and also announcing new data for Mounjaro in treating metabolic dysfunction-associated steatohepatitis (MASH), a form of liver disease previously called NASH. Initially, shares traded up 5%.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Caregivers of transplant patients call for more support, training

hotspot

WSS

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

As JPM 2024 winds down, some health tech firms project optimism

John Green on his newest strategy for fighting tuberculosis

RaDonda Vaught links Vanderbilt hospital issues to patient death

DeSantis can now import cheaper drugs. But will Biden get credit?

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

focus

fashion

entertainment

Continuity nursing helped my family in our darkest PICU moments

As AI in medicine takes off, can 'human in the loop' prevent harm?

Activists slam private health insurers over coverage restrictions

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

Duchenne breakthrough therapy leaves behind pioneering families

John Green on his newest strategy for fighting tuberculosis

Walensky prepares to leave CDC — and Congress — behind

Pushing for an NIH office for post

Guidelines to prevent youth baseball injuries need more muscle

Medicare coverage of Wegovy, once blocked, now looks possible

entertainment

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

Readout Newsletter: Bristol, Sangamo, Gilead, and more

How to save health care price transparency rules

Steward Health Care Massachusetts hospitals face fiscal disaster

Change Healthcare outage fallout shows need for new oversight

Why depression after traumatic brain injury is distinct

leisure time

focus

hotspot

focus